Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260516 | 0.93 | HTR2C (0.50) | HTR2CAGTR2CHRM1CHRM4CHRM5 | |
| SCHEMBL12798144 | 0.87 | AGTR2 (0.54) | HTR2CAGTR2TACR3NPSR1NPC1 | |
| SCHEMBL7646821 | 0.87 | AGTR2 (0.54) | HTR2CAGTR2TACR3NPSR1NPC1 | |
| SCHEMBL8351858 | 0.87 | AGTR2 (0.54) | HTR2CAGTR2TACR3NPSR1NPC1 | |
| SCHEMBL13613244 | 0.86 | AGTR2 (0.50) | HTR2CAGTR2TACR3NPC1RAB9A | |
| SCHEMBL16276273 | 0.85 | HTR2C (0.49) | HTR2CAGTR2TACR3NPSR1NPC1 | |
| SCHEMBL13910588 | 0.82 | TACR3 (0.47) | HTR2CAGTR2TACR3NPC1RAB9A | |
| SCHEMBL12848965 | 0.82 | HTR2C (0.56) | HTR2CAGTR2TACR3NPSR1NPC1 | |
| SCHEMBL17061337 | 0.81 | AGTR2 (0.52) | HTR2CAGTR2CHRM1CHRM4CHRM5 | |
| SCHEMBL16647852 | 0.81 | HTR2C (0.47) | HTR2CAGTR2PKMNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291902-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | PRSS1, SERPINB1, SPINT2 | HTR2C 2850/4885AGTR2 3306/4885CHRM1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.